Back to Results

A5380: A Phase II Trial of Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)

Study category: Infectious Diseases

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

- Age at least 18 years of age - With or without HIV. If living with HIV, on a stable antiretroviral regimen or untreated due to lack of indication per physician. - HIV RNA <50 and CD4 >100 - May not have Hepatitis B or C - Recently infected with HCV - Cannot be pregnant or breastfeeding - Must be willing to use birth control to prevent pregnancy - Must be willing to come to study visits - Must be able to swallow pills - May not have other known liver disease

Phase

II - Research Studies that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Thomas Campbell

Thomas Campbell

Study ID

Protocol Number: 20-0303

More information available at ClinicalTrials.gov: NCT04042740

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers